ARTELO BIOSCIENCES, INC. (ARTL) Form 8-K Material Events
ARTELO BIOSCIENCES, INC. (ARTL) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ARTL
CIK: 1621221
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
MaloneBailey, LLP
Auditor SinceSince 8/31/2017 12:00:00 AM
Lead Engagement PartnerJoe Longoria
Audit LocationHouston, Texas, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-09 | 2026-10-09 | FORM 8-K | 0001640334-26-001665 | View SEC Doc Filr Page |
| 8-K | 2026-08-27 | 2026-08-26 | FORM 8-K | 0001640334-26-001421 | View SEC Doc Filr Page |
| 10-Q/A | 2026-08-20 | 2026-06-30 | FORM 10-Q/A | 0001640334-26-001400 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001172661-26-003551 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-13 | — | SCHEDULE 13G/A Filing | 0001213900-26-088826 | View SEC Doc Filr Page |
| 10-Q | 2026-08-12 | 2026-06-30 | FORM 10-Q | 0001640334-26-001323 | View SEC Doc Filr Page |
| 4 | 2026-07-21 | 2026-07-17 | FORM 4 | 0001640334-26-001231 | View SEC Doc Filr Page |
| 4 | 2026-07-21 | 2026-07-17 | FORM 4 | 0001640334-26-001229 | View SEC Doc Filr Page |
| 4 | 2026-07-21 | 2026-07-17 | FORM 4 | 0001640334-26-001227 | View SEC Doc Filr Page |
| 4 | 2026-07-21 | 2026-07-17 | FORM 4 | 0001640334-26-001225 | View SEC Doc Filr Page |
| 4 | 2026-07-21 | 2026-07-17 | FORM 4 | 0001640334-26-001223 | View SEC Doc Filr Page |
| 4 | 2026-07-21 | 2026-07-17 | FORM 4 | 0001640334-26-001221 | View SEC Doc Filr Page |
| 8-K | 2026-07-17 | 2026-07-17 | FORM 8-K | 0001640334-26-001198 | View SEC Doc Filr Page |
| DEFA14A | 2026-07-16 | — | DEFA14A | 0001640334-26-001189 | View SEC Doc Filr Page |
| DEFA14A | 2026-07-16 | — | DEFA14A | 0001640334-26-001186 | View SEC Doc Filr Page |
| DEFA14A | 2026-07-02 | — | DEFA14A | 0001640334-26-001147 | View SEC Doc Filr Page |
| PRER14A | 2026-06-22 | — | PRER 14A | 0001640334-26-001106 | View SEC Doc Filr Page |
| ARS | 2026-06-05 | 2025-12-31 | ARS | 0001640334-26-001011 | View SEC Doc Filr Page |
| DEFA14A | 2026-06-05 | — | DEFA14A | 0001640334-26-001009 | View SEC Doc Filr Page |
| DEF 14A | 2026-06-05 | 2026-07-17 | DEF 14A | 0001640334-26-001007 | View SEC Doc Filr Page |
| 8-K | 2026-05-27 | 2026-05-26 | FORM 8-K | 0001640334-26-000973 | View SEC Doc Filr Page |
| PRE 14A | 2026-05-26 | 2026-07-17 | FORM PRE 14A | 0001640334-26-000969 | View SEC Doc Filr Page |
| 424B5 | 2026-05-26 | — | 424B5 | 0001640334-26-000966 | View SEC Doc Filr Page |
| EFFECT | 2026-05-19 | — | EFFECT Filing | 9999999995-26-001705 | View SEC Doc Filr Page |
| 424B5 | 2026-05-18 | — | FORM 424B5 | 0001640334-26-000926 | View SEC Doc Filr Page |